Helix BioPharmaHBPCF 28 Market Cap is $71.48 Mil as of Jun. 25, 2026. GuruFocus rates HBPCF with a GF Score™ of 28/100. Among 1,431 Biotechnology companies, Helix BioPharma ranks worse than 57.37% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Helix BioPharma's share price for the quarter that ended in Apr. 2026 was $1.73. Helix BioPharma's Shares Outstanding (EOP) for the quarter that ended in Apr. 2026 was 76.38 Mil. Therefore, Helix BioPharma's market cap for the quarter that ended in Apr. 2026 was $132.13 Mil.
Helix BioPharma's quarterly market cap
stayed the same
from Oct. 2025 ($132.42 Mil) to Jan. 2026 ($132.42 Mil) but then
declined
from Jan. 2026 ($132.42 Mil) to Apr. 2026 ($132.13 Mil).
Helix BioPharma's annual market cap
increased
from Jul. 2023 ($31.42 Mil) to Jul. 2024 ($40.74 Mil) and
increased
from Jul. 2024 ($40.74 Mil) to Jul. 2025 ($44.49 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Helix BioPharma's Enterprise Value for Today is $69.74 Mil.
Helix BioPharma (OTCPK:HBPCF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Helix BioPharma Market Cap Related Terms
Helix BioPharma Market Cap Historical Data
* Premium members only.
The historical data trend for Helix BioPharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Helix BioPharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helix BioPharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Helix BioPharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Helix BioPharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Helix BioPharma's Market Cap for the fiscal year that ended in Jul. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Helix BioPharma (HBPCF) has a Market Cap of $71.48 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Helix BioPharma and its competitors. According to the industry distribution chart, Helix BioPharma ranks #821 out of 1431 companies in the Biotechnology industry, placing it in the top 57.4%.
Is Helix BioPharma's Market Cap too high?
Helix BioPharma's current Market Cap is $71.48 Mil. The Biotechnology industry median Market Cap is 117.63. Helix BioPharma's value of $71.48 Mil is 39.2% below this industry median. Based on the distribution chart, Helix BioPharma ranks #821 out of 1431 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helix BioPharma ranks #821 out of 1431 companies for Market Cap. This places Helix BioPharma in the lower half of its industry. The industry median Market Cap is 117.63. Helix BioPharma's value of $71.48 Mil is 39.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Helix BioPharma's current Market Cap of $71.48 Mil is 39.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Helix BioPharma and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Helix BioPharma's current Market Cap is $71.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current Market Cap of $71.48 Mil. The current Market Cap is $71.48 Mil and 39.2% below the Biotechnology industry median of 117.63. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current Market Cap is $71.48 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score
Get the complete analysis for HBPCF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HBPCF has been successfully added to your 
